Adocia SA (ADOC.PA), a clinical-stage biotechnology company, surged by 12.47% on Monday on the CAC 40 exchange, continuing an upward trend despite a fall of 0.46% across all indexes.
Adocia’s Recent Performance
Adocia stock closed at EUR4.09 last Friday, significantly under its 52-week high of EUR5.60 indicating there may be further gains for investors in Adocia shares.
About Adocia
Lyon-based BioChaperone Pharma specialises in creating formulations of existing therapeutic proteins and peptides to treat diabetes and other metabolic diseases using its revolutionary BioChaperone technology. This proprietary innovation facilitates more efficient molecular delivery of therapeutic proteins thus increasing treatment efficacy.
Adocia’s Product Pipeline
Adocia offers an impressive product pipeline in both clinical and preclinical development stages, including insulin formulations such as BioChaperone Lispro U100/U200 and Combo to novel solutions to treat diabetes and obesity like BioChaperone GluExe; which combines glucagon with exenatide.
Adocia’s Financial Status
Adocia boasts advanced technological prowess; yet their trailing twelve month earnings per share (EPS) stands at EUR-0.89 indicating they are not yet profitable. Adocia’s revenue growth may give prospective investors hope: year-on-year quarterly revenue increased 96.9% with total twelve month revenue reaching 17.36M.
Investor Consideration
Adocia’s recent stock gains and impressive revenue growth indicate an increased investor trust; however, when making investment decisions one must carefully weigh this against their lack of profitability and take other considerations into account. Adocia stands out in the stock market due to its scientific innovation, robust product pipeline and substantial revenue growth potential; therefore making it worthy of consideration as an investment.
More news about ADOCIA (ADOC.PA).
